Literature DB >> 17632171

The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer.

Rauf Taner Divrik1, Ali Sahin, Muammer Altok, Nuri Unlü, Ferruh Zorlu.   

Abstract

PURPOSE: We determined the frequency of hydronephrosis at initial diagnosis, and its effect on recurrence and progression in patients with superficial bladder cancer.
MATERIALS AND METHODS: Between January 1993 and April 2006 we retrospectively reviewed the records of 931 patients with superficial transitional cell carcinoma of the bladder at our institute. Hydronephrosis status was determined by excretory urogram, ultrasound or computerized tomography of the abdomen and pelvis at initial evaluation. The number of tumors, tumor size, tumor location, T category (pTa vs pT1) and histological grade were assessed at study entry. The absence or presence of unilateral or bilateral upper tract obstruction/hydronephrosis was recorded for all cohorts. We examined the frequency of hydronephrosis in patients with superficial bladder carcinoma according to T status and investigated the relationship between hydronephrosis, and recurrence-free and progression-free survival for pTa and pT1 stage. The end points assessed were recurrence and progression.
RESULTS: Histopathological results showed that 63.8% of all superficial bladder cancer cases were pT1 stage. Preoperative radiological evaluation revealed unilateral and bilateral hydronephrosis in 70 (7.5%) and 19 (2.1%) patients in all cohorts, respectively. Of patients with pTa tumors 304 (90.2%) had low grade lesions and 207 (61.4%) had a single tumor. Unilateral and bilateral hydronephrosis was detected in 16 (4.7%) and 4 (1.2%) patients with pTa, respectively. Of patients with pT1 tumors 196 (33.0%) had low grade lesions and 283 (47.6%) had a single tumor. Unilateral and bilateral hydronephrosis was detected in 54 (9.1%) and 15 (2.5%) patients with pT1 disease, respectively. The increased probability of hydronephrosis was detected in higher stage, higher grade multiple tumors and in tumors larger than 3 cm. Of 931 patients 37.9% had at least 1 recurrence with an incidence of 27.3% for Ta and 43.9% for T1 disease. The recurrence rate was 52.8% for patients with hydronephrosis, that is 35.0% for Ta and 58.0% for T1 disease. Median time to first recurrence was 22 months. Multivariate Cox analysis confirmed that T category, grade, tumor size and hydronephrosis were significant prognostic variables of recurrence. Of the cases 11% progressed to muscle invasive bladder cancer. Multivariate analysis revealed that progression was statistically significant for T category, disease grade, multiplicity, tumor size and the presence or absence of hydronephrosis.
CONCLUSIONS: Unilateral/bilateral hydronephrosis detected at the first evaluation at diagnosis of superficial bladder tumors is an independent prognostic factor for recurrence and progression.

Entities:  

Mesh:

Year:  2007        PMID: 17632171     DOI: 10.1016/j.juro.2007.05.054

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  10 in total

1.  Bladder cancer: is contrast-enhanced CT necessary for following up NMIBC?

Authors:  Mesut Remzi; Shahrokh F Shariat
Journal:  Nat Rev Urol       Date:  2013-08-06       Impact factor: 14.432

2.  Radical cystectomy for the treatment of T1 bladder cancer: the Canadian Bladder Cancer Network experience.

Authors:  Venu Chalasani; Wassim Kassouf; Joseph L Chin; Yves Fradet; Armen G Aprikian; Adrian S Fairey; Eric Estey; Louis Lacombe; Ricardo Rendon; David Bell; Ilias Cagiannos; Darrell Drachenberg; Jean-Baptiste Lattouf; Jonathan I Izawa
Journal:  Can Urol Assoc J       Date:  2011-04       Impact factor: 1.862

3.  Upper urinary tract urothelial carcinoma: what have we learned in the last 4 years?

Authors:  Mesut Remzi; Shahrokh Shariat; Wilhelm Huebner; Harun Fajkovic; Christian Seitz
Journal:  Ther Adv Urol       Date:  2011-04

Review 4.  Urothelial carcinoma of the bladder: definition, treatment and future efforts.

Authors:  Sandip M Prasad; G Joel Decastro; Gary D Steinberg
Journal:  Nat Rev Urol       Date:  2011-10-11       Impact factor: 14.432

5.  Predictive role of preoperative hydronephrosis on poor pathological outcomes and prognosis in upper tract urothelial carcinoma patients: Experience from a nationwide high-volume center in China.

Authors:  Zheng Zhang; Dong Fang; Xiaopeng Chen; Xuesong Li; Gengyan Xiong; Lei Zhang; Qun He; Liqun Zhou
Journal:  Oncol Lett       Date:  2015-08-28       Impact factor: 2.967

6.  Tumour stage on re-staging transurethral resection predicts recurrence and progression-free survival of patients with high-risk non-muscle invasive bladder cancer.

Authors:  Mohamed Bishr; Jean-Baptiste Lattouf; Mathieu Latour; Fred Saad
Journal:  Can Urol Assoc J       Date:  2014-05       Impact factor: 1.862

7.  Predicting recurrence of nonmuscle-invasive bladder cancer (Ta-T1): A study based on 477 patients.

Authors:  Mengxin Lu; Song Chen; Qiang Zhou; Lu Wang; Tianchen Peng; Gang Wang
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

8.  A Comparison of the Anesthetic Methods for Recurrence Rates of Bladder Cancer after Transurethral Resection of Bladder Tumors Using National Health Insurance Claims Data of South Korea.

Authors:  Sang Won Lee; Bum Sik Tae; Yoon Ji Choi; Sang Min Yoon; Yoon Sook Lee; Jae Hwan Kim; Hye Won Shin; Jae Young Park; Jae Hyun Bae
Journal:  J Clin Med       Date:  2022-02-21       Impact factor: 4.241

9.  Clinical and prognostic value of preoperative hydronephrosis in upper tract urothelial carcinoma: a systematic review and meta-analysis.

Authors:  Yuejun Tian; Yuwen Gong; Yangyang Pang; Zhiping Wang; Mei Hong
Journal:  PeerJ       Date:  2016-06-21       Impact factor: 2.984

10.  Impact of double J stenting or nephrostomy placement during transurethral resection of bladder tumour on the incidence of metachronous upper urinary tract urothelial cancer.

Authors:  Marie C Hupe; Lukas Dormayer; Tomasz Ozimek; Julian P Struck; Martin J P Hennig; Melanie Klee; Christoph A J von Klot; Markus A Kuczyk; Axel S Merseburger; Mario W Kramer
Journal:  BMC Cancer       Date:  2020-02-21       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.